Stay updated on Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page.

Latest updates to the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page revision label changed from v3.5.2 to v3.5.3, indicating a newer version of the page. This change is a metadata update rather than a modification to study data or content.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedFooter revision label updated from Revision: v3.5.0 to Revision: v3.5.2.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedAdded 'Carcinoma of esophagus' to the conditions listed for the study.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check56 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check78 days agoChange DetectedGastric cancer is now listed as a condition term, and a Genetic and Rare Diseases Information Center resource has been added under Resources.SummaryDifference0.2%

Stay in the know with updates to Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page.